A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
about
A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
A Multicenter Randomized Phase ...... us Either S-1 or Capecitabine.
@en
A Multicenter Randomized Phase ...... us Either S-1 or Capecitabine.
@nl
type
label
A Multicenter Randomized Phase ...... us Either S-1 or Capecitabine.
@en
A Multicenter Randomized Phase ...... us Either S-1 or Capecitabine.
@nl
prefLabel
A Multicenter Randomized Phase ...... us Either S-1 or Capecitabine.
@en
A Multicenter Randomized Phase ...... us Either S-1 or Capecitabine.
@nl
P2093
P2860
P356
P1476
A Multicenter Randomized Phase ...... us Either S-1 or Capecitabine.
@en
P2093
Bum Jun Kim
Hye Sook Han
Jin Won Kim
Keun-Wook Lee
Mi-Jung Kim
Sook Ryun Park
Young Iee Park
P2860
P304
P356
10.4143/CRT.2016.216
P577
2016-10-18T00:00:00Z